10-Q: AEON Biopharma Q2 2025: Biosimilar Focus, Capital Infusion

AEON Biopharma reported a strategic shift to a biosimilar pathway for ABP-450, raised $18.3M in a public offering, and faces a going concern warning despite improved cash position.

Summary

• Net income for the six months ended June 30, 2025, was $2.5 million, a significant decrease from $46.1 million in the prior year.
• Cash and cash equivalents increased to $8.4 million as of June 30, 2025, from $13,000 at December 31, 2024, primarily due to a public offering.
• The company discontinued Phase 2 clinical trials for episodic and chronic migraine in May 2024 after failing to meet primary or secondary endpoints, implementing cash preservation measures.
• A strategic reprioritization was announced on July 9, 2024, to pursue a Section 351(k) biosimilar regulatory pathway for ABP-450, using AbbVie Inc.'s Botox as a reference product.
• Research and development (R&D) expenses decreased by 81% to $1.9 million for the six months ended June 30, 2025, from $10.2 million in the prior year, mainly due to the wind-down of Phase 2 clinical trials.
• Selling, general and administrative (SG&A) expenses decreased by 20% to $6.4 million for the six months ended June 30, 2025, from $8.0 million in the prior year, attributed to reduced legal expenses and headcount.
• A public offering in January 2025 generated net proceeds of approximately $18.3 million.
• The company received a notice of non-compliance from NYSE American on February 3, 2025, regarding its stockholders' equity, but its plan to regain compliance was accepted, granting until August 3, 2026.
• Management concluded there is substantial doubt about the company's ability to continue as a going concern, with sufficient cash to fund operations only into the fourth quarter of 2025.
• A 1-for-72 reverse stock split was effected on February 24, 2025.

Sentiment

Score: 3

Explanation: The company faces severe financial distress with a going concern warning and significant accumulated deficit. While a recent capital raise and strategic shift to a biosimilar pathway offer a potential lifeline, the discontinuation of key clinical trials and ongoing operational losses indicate a challenging path forward. The material weaknesses in internal controls add to the negative sentiment.

Positives

• Cash and cash equivalents significantly increased to $8.4 million as of June 30, 2025, from $13,000 at December 31, 2024.
• Net cash used in operating activities decreased to $10.0 million for the six months ended June 30, 2025, from $16.7 million in the prior year.
• A successful public offering raised $18.3 million in net proceeds.
• NYSE American accepted the plan to regain compliance with listing standards, providing until August 3, 2026.
• The Phase 2 cervical dystonia study met all primary and key secondary endpoints, supporting further development.
• The strategic shift to a biosimilar pathway for ABP-450 (using Botox as reference) could offer a unique pricing model and improved reimbursement for therapeutic uses.
• Stockholders' deficit improved to $(15.852) million at June 30, 2025, from $(28.569) million at December 31, 2024.

Negatives

• Net income for the six months ended June 30, 2025, was $2.5 million, a substantial decrease from $46.1 million in the prior year.
• Basic and diluted net income per share significantly decreased from $87.15 to $0.32 and $0.31, respectively, for the six months ended June 30, 2025, compared to the prior year.
• Discontinuation of Phase 2 clinical trials for episodic and chronic migraine due to failure to meet primary or secondary endpoints.
• Accumulated deficit remains high at $429.1 million as of June 30, 2025.
• Management concluded there is substantial doubt about the company's ability to continue as a going concern, with cash only sufficient into the fourth quarter of 2025.
• Identified material weaknesses in internal control over financial reporting, including lack of sufficient qualified resources for complex transactions and segregation of duties.
• Incurred a $75.6 million loss on the issuance of warrants in the first quarter of 2025.
• An ongoing legal proceeding with Odeon Capital Group LLC for a $1.25 million deferred underwriting fee.

Risks

• Substantial doubt about the ability to continue as a going concern due to recurring losses, net capital deficiency, and negative cash flows from operations.
• Need for substantial additional financing to fund operations and further development of ABP-450, with no assurance of availability on reasonable terms or at all.
• Potential for significant dilution of existing shareholders if equity is used as a source of financing.
• Dependency on the clinical and commercial success of current and future product candidates, including obtaining regulatory approval.
• Uncertainty of broad adoption of approved products by physicians and patients.
• Significant competition in the pharmaceutical industry.
• Reliance on Daewoong Pharmaceutical Co., Ltd. as an exclusive and sole supplier for ABP-450, with potential material adverse effects if the license and supply agreement is terminated or rights are lost.
• Risk of delisting from NYSE American if compliance with listing standards is not regained by August 3, 2026.
• Material weaknesses in internal control over financial reporting, posing a risk of material misstatement not being prevented or detected timely.
• The exercise price of Private Placement Warrants ($828.00) is significantly higher than the current stock price ($0.713 as of August 7, 2025), making cash exercise unlikely and limiting potential capital from this source.

Future Outlook

The company anticipates completing analytical studies for its ABP-450 biosimilar program in the third quarter of 2025, followed by an expected Biosimilar Biological Product Development (BPD) Type 2a meeting with the FDA in the fourth quarter of 2025. It expects to continue incurring significant operating losses and will require additional funding beyond the fourth quarter of 2025 to advance ABP-450 development and commercialization. The company aims to regain compliance with NYSE American listing standards by August 3, 2026.

Management Comments

• We are a biopharmaceutical company seeking accelerated and full-label United States (U.S.) market entry by developing our botulinum toxin complex, prabotulinumtoxinA injection (ABP-450) as a BOTOX biosimilar for debilitating medical conditions.
• We believe that ABP-450 has potential across a broad range of target indications and we plan to continue to explore additional development programs that satisfy our product assessment screens.
• We believe that the positive data derived from these preclinical and clinical studies will support the clinical development and anticipated future safety labeling of ABP-450 for migraine and cervical dystonia, in addition to other indications, including our 351(k) biosimilar program, at all contemplated dose ranges.
• This pricing model would be unique to us within the current therapeutic neurotoxin market, and we believe it would allow physicians to provide treatment with ABP-450 at a more competitive or the same net price as the market leader after rebates and discounts.
• We have concluded that we do not have sufficient cash to fund our operations for 12 months from the date of our financial statements without additional financing, and as a result, there is substantial doubt about our ability to continue as a going concern.
• As of the date of this Report, we have sufficient cash to fund our operating plan into the fourth quarter of 2025.

Industry Context

The biopharmaceutical industry, particularly in the botulinum toxin market, is highly competitive. AEON Biopharma's shift to a biosimilar pathway for ABP-450, targeting Botox's therapeutic indications, positions it to potentially disrupt a significant market segment estimated at $3.3 billion. The strategy to pursue a Section 351(k) BLA, which could allow for a unique pricing model based solely on therapeutic sales, aims to address a key reimbursement challenge faced by existing botulinum toxins that combine cosmetic and therapeutic sales in their average selling price (ASP) calculations. This could offer a competitive advantage by facilitating more favorable physician reimbursement and enabling financial incentives for payors/providers. However, the success of this strategy hinges on successful analytical studies, FDA approval, and effective commercialization in a market dominated by established players like AbbVie (Botox).

Comparison to Industry Standards

• Biosimilar Development: The company is pursuing a Section 351(k) biosimilar pathway for ABP-450, using AbbVie Inc.'s Botox as a reference product. This is a standard regulatory approach for biosimilars, aiming to demonstrate high similarity to an approved biologic.
• Clinical Trial Outcomes: The discontinuation of Phase 2 migraine trials due to not meeting primary or secondary endpoints is a common occurrence in drug development, highlighting the high-risk nature of the biopharma industry. In contrast, the Phase 2 cervical dystonia study met all primary and key secondary endpoints, which is a positive indicator for that specific indication, comparable to successful early-stage clinical results seen in other therapeutic areas.
• Financial Health: The 'going concern' warning and recurring losses are not uncommon for early-stage biopharmaceutical companies heavily invested in R&D. However, the significant accumulated deficit of $429.1 million and the need for continuous capital raises (e.g., $18.3 million public offering, $15.0 million convertible notes) indicate a high burn rate relative to its current cash position, which is typical for companies without commercialized products but still a concern for investors.
• Market Opportunity: The target market for therapeutic botulinum toxins is estimated at $3.3 billion (based on AbbVie's Botox revenues), indicating a substantial opportunity if ABP-450 gains approval and market acceptance. This market size is comparable to other high-value therapeutic areas targeted by biopharma companies.

Management Changes

Corporate Governance

Legal Proceedings

• Lawsuit filed by Odeon Capital Group LLC on September 18, 2023, alleging failure to pay a $1.25 million deferred underwriting fee.
• Company successfully obtained dismissal of Odeon's non-breach of contract claims (tort claims, breach of covenant, punitive damages) in April 2024.
• Odeon's breach of contract claim is proceeding to trial, with neither party prevailing on summary judgment motions filed in March 2025.

Related Party Transactions

• Daewoong Convertible Notes: $15.0 million principal amount, with a fair value of $15.174 million as of June 30, 2025. Daewoong is also the exclusive and sole supplier of ABP-450 and a party to the License and Supply Agreement.
• License and Supply Agreement with Daewoong: Daewoong manufactures and supplies ABP-450, granting an exclusive license for therapeutic indications in certain territories. The agreement includes a termination clause if the company ceases to commercialize or advance clinical studies of ABP-450 in specified territories, giving Daewoong the right to purchase Know-How for $1.00.

Stakeholder Impact

• Shareholders: Significant dilution risk from future equity financings, especially given the 'going concern' warning and the need for additional capital. The 1-for-72 reverse stock split and the $75.6 million loss on warrant issuance also impact shareholder value. The NYSE American non-compliance notice and potential delisting pose a risk to liquidity and investment value.
• Employees: Headcount reduction in Q2 2024 to preserve cash. New incentive award plans (2023 and 2025) offer stock-based compensation, potentially aligning interests with company performance, but also subject to stock price volatility.
• Creditors (Daewoong): Daewoong holds $15.0 million in convertible notes, with an annual interest rate of 15.79%, indicating a significant financial stake and a higher risk profile for this debt. The termination clause in the License Agreement provides Daewoong with a protective right if the company fails to advance ABP-450.
• Customers/Patients (Future): The strategic shift to a biosimilar pathway for ABP-450 aims to bring a new therapeutic option to market, potentially offering a more competitive pricing model for physicians and patients. However, the discontinuation of migraine trials means those patients will not benefit from ABP-450 for that indication from AEON.
• Regulatory Bodies (FDA, NYSE American): The company is actively engaging with the FDA on the biosimilar pathway and has submitted a plan to NYSE American to regain compliance, indicating efforts to meet regulatory and listing requirements.

Next Steps

• Complete analytical studies for ABP-450 biosimilar program in Q3 2025.
• Hold a Biosimilar Biological Product Development (BPD) Type 2a meeting with the FDA in Q4 2025 to review analytical study results.
• Actively secure additional capital to fund operations and further development of ABP-450.
• Implement and test enhanced controls to remediate material weaknesses in internal control over financial reporting.
• Regain compliance with NYSE American listing standards by August 3, 2026.
• May commence a Phase 3 study in cervical dystonia pending results of comparative analytical studies and FDA discussions.
• Continue to evaluate various pathways to efficiently advance the gastroparesis clinical development program.
• Continue to explore additional development programs for ABP-450 in other disorders.
• Proceed to trial for the breach of contract claim in the lawsuit filed by Odeon Capital Group LLC.

Key Dates

Recommendation

The company faces severe financial challenges, including a 'going concern' warning and a substantial accumulated deficit. While a recent capital raise provided some liquidity, it is insufficient to fund operations beyond Q4 2025 without further financing, which is uncertain. The discontinuation of key Phase 2 migraine trials represents a significant clinical setback, and the strategic pivot to a biosimilar pathway, while potentially viable, is a long-term endeavor with no guaranteed success. Material weaknesses in internal controls and ongoing litigation add to the operational risks. The current stock price of $0.713 (as of August 7, 2025) is far below the private placement warrant exercise price, indicating a lack of confidence in significant near-term appreciation. Given the high operational burn rate, the need for substantial future capital, and the inherent risks of early-stage biopharma development coupled with financial instability, a seasoned investor would likely recommend selling to mitigate further losses.

Keywords

Biopharma, Botulinum Toxin, ABP-450, Biosimilar, BOTOX, SEC Filing, 10-Q, Financial Results, Clinical Trials, Migraine Treatment, Cervical Dystonia, Gastroparesis, Regulatory Pathway, FDA, Going Concern, Capital Raise, Public Offering, Warrants, NYSE American, Corporate Governance, Risk Management, Daewoong Pharmaceutical